The JGH is excited to present the 58th Annual André Aisenstadt Clinical Day, an expert panel on COVID-19, featuring six renowned experts. This day will include talks on the myriad of topics related to psychiatry, obstetrics, thrombosis, long-term complications of Covid, as well as the historical making of the mRNA vaccines. This event is accredited by the FMSQ and attendees will receive a CME certificate post-event.
Date: October 28, 2021
Time: 8:45 a.m. to 3:30 p.m.
In departments across the hospital, the personnel responded to the unique challenges posed by COVID-19 with grace and skill. We are pleased to recognize their selfless contributions and demonstrated leadership.
Marc Afilalo, MD, MCFP(EM), CSPQ, FACEP, FRCP
Director, Emergency Department, Jewish General Hospital
Professor and Chair, Department of Emergency Medicine, McGill University
Georges Bendavid, B. Ing, M.Sc
Director of Technical Services, Integrated University Health and Social Services Centre for West-Central Montreal
E. Ruth Chaytor, MD, FRCSC
Associate Professor of Surgery, McGill University
Orthopaedic Foot and Ankle Surgeon & Chief of Surgical Services, Jewish General Hospital
Dr. Justin Cross
Chief Digital Health Officer for the Integrated Health and Social Services University Network for West-Central Montreal
Chief of Laundry and Linen Services for the Integrated University Health and Social Services Centre for West-Central Montreal and President of the Board of Directors of the CPE Les frimousses for the CCOMTL
Khan Du Dinh
Associate to the Director DRHCAJ- Global security, Integrated University Health and Social Services Centre for West-Central Montreal
Director of Human Resources, Communications and Legal Affairs for the Integrated University Health and Social Services Centre for West-Central Montreal
Roderick R. McInnes, CM, MD, PhD, FRSC
Alva Chair in Human Genetics
Lady Davis Institute
Carmela Pepe, MD, FRCPC
Assistant Professor of Medicine, Division of Pulmonary Diseases
Department of Medicine, Medical Director Covid Units and K7 CTU, Jewish General Hospital
April Shamy, MD, FRCPC
Associate Professor of Medicine, McGill University
Division of Hematology, Department of Medicine, Medical Director Covid Units and K7 CTU, Jewish General Hospital
Roberta Shear, MD, FRCSC
Director of Obstetrics & OBS Ultrasound, Jewish General Hospital
Assistant Program Director, McGill OBGYN Residency Program
Assistant Professor, McGill University
Elliott Silverman, PMP, CRP
Director of Logistics and the Internet of Things, Jewish General Hospital
Lucie Tremblay, inf., M.Sc., Adm.A., CHE, ASC
Director of Nursing, Integrated University Health and Social Services Centre for West-Central Montreal
Department Head – Environmental Services, Integrated Health and Social Services University Network for West-Central Montreal
Paul Warshawsky, MD, CM, FRCP(C)
Chief, Adult Critical Care Medicine, Jewish General Hospital
Assistant Professor, Department of Medicine, McGill University
Karl Weiss, MD, MSc, FRCPC
Chief, Division of Infectious Diseases, Jewish General Hospital, Professor of Medicine, McGill University, Department of Medicine
LEARN MORE ABOUT OUR GUEST LECTURERS
EMILIA LIANA FALCONE, MD, PHD, FRCPC
Director, IRCM Post-COVID-19 Research Clinic; Director, Microbiome and Mucosal Defence Research Unit, Institut de recherches cliniques de Montréal (IRCM); Assistant Clinical Professor, Université de Montréal
Dr. Emilia Liana Falcone is the Director of the IRCM Post-COVID-19 research clinic and the Director of the Microbiome and Mucosal Defense Research Unit at the Montreal Clinical Research Institute (IRCM). She is also an Assistant Clinical Professor in the Department of Medicine at Université de Montréal, an Infectious Diseases Specialist at Centre Hospitalier de l’Université de Montréal (CHUM), and holds a Canada Research Chair in the Role of the Microbiome in Primary Immunodeficiency. During the COVID-19 pandemic, Dr. Falcone established the IRCM Post-COVID-19 (IPCO) research clinic, the first clinic of its kind in Montreal. The IPCO research clinic integrates the clinical evaluation of post-acute COVID-19 sequelae with a research protocol (clinicaltrials.gov; NCT04736732) and biobank aimed at understanding the mechanisms underlying the pathogenesis of the post-COVID-19 condition.
DAVID FISMAN, MD
Professor of Epidemiology at the Dalla Lana School of Public Health, University of Toronto, Lead of the Pandemic Readiness Stream at the University of Toronto Institute for Pandemics
Dr. Fisman is a physician-epidemiologist with research interests at the intersection of applied epidemiology, mathematical modeling, and applied health economics. He trained in medicine and epidemiology at Western, McGill, Brown and Harvard Universities, and has held faculty appointments at Drexel, McMaster, Princeton and the University of Toronto, where he is currently Professor of Epidemiology. He currently serves on Ontario’s COVID Science and Modeling tables and holds emergency COVID-19 research funds from Canadian Institutes of Health Research. He leads the Pandemic Readiness stream at the new University of Toronto Institute for Pandemics.
SUSAN KAHN, MD, PHD
Professor of Medicine, McGill University
Dr. Kahn is a clinical epidemiologist and internist based at the Jewish General Hospital, where she is the founder and director of the Centre of Excellence in Thrombosis and Anticoagulation Care. She is appointed as Professor with Tenure and Associate Chair-Research in the Department of Medicine, McGill University. She founded the McGill Thrombosis Fellowship, for which she was Program Director from 2007-2018. She is co-Director of the CIHR-funded CanVECTOR Network, a Canadian national venous thromboembolism research and training network. In 2016, she was elected to Fellowship in the Canadian Academy of Health Sciences, considered one of the highest honors for members of the Canadian health sciences community.
VANESSA POLIQUIN, MD
Associate Professor, Dept. Obstetrics, Gynecology and Reproductive Sciences, Section Head of the Division of Obstetrics, Women’s Hospital, Winnipeg Health Sciences
Dr. Poliquin attended medical school at the University of Western Ontario and completed her residency training in Obstetrics & Gynecology at the University of Manitoba. Following her residency, she pursued a fellowship in Reproductive Infectious Diseases and a Master’s Degree in Epidemiology through the London School of Hygiene and Tropical Medicine. Since completing her training, Dr. Poliquin has provided clinical service in reproductive infectious diseases and is now Section Head of Obstetrics at Women’s Hospital Winnipeg Health Sciences. Dr. Poliquin runs a wet-lab affiliated with the Child Health Research Institute of Manitoba and her primary research program, THRIVE, looks at the vaginal mucosal system in the context of BV, candidiasis and HPV. Dr. Poliquin’s research also involve a number of clinical studies, including the national CANCOVID-Preg collaboration. She has received several accolades, most notably the CMA’s Early Career Leader Award for 2020. Poliquin chairs Manitoba’s Shared Health Provincial Obstetrical Working group as well as the Infectious Diseases Committee for the Society of Obstetrician and Gynaecologists of Canada and wearing these hats, she played a key role in guiding prenatal providers in Canada through the thick of the pandemic.
CECILE ROUSSEAU, MD
Professor, Division of Social and Cultural Psychiatry, McGill University
Dr. Cécile Rousseau, MD is professor of the Division of Social and Cultural Psychiatry at McGill University. She received her training in medicine and psychiatry at the University of Sherbrooke, Université de Montreal and McGill. She has worked extensively with immigrant and refugee communities, developing specific school-based interventions and leading policy-oriented research. Presently her research focuses on intervention and prevention programs to address violent radicalization. During the COVID-19 pandemic, she led a wide community intervention program and conducted a number of research projects on the mental health consequences of this context on Canadian communities.
DREW WEISSMAN, MD
Roberts Family Professor in Vaccine Research, Perelman School of Medicine, University of Pennsylvania
Drew Weissman, M.D., Ph.D. is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman, in collaboration with Dr. Katalin Karikó, discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. The nucleoside-modified mRNA-lipid nanoparticle vaccine platform Dr. Weissman’s lab created is used in the first 2 approved COVID-19 vaccines by Pfizer/BioNTech and Moderna. They continue to develop other vaccines that induce potent antibody and T cell responses with mRNA–based vaccines. Dr. Weissman’s lab also develops methods to replace genetically deficient proteins, edit the genome, and specifically target cells and organs with mRNA-LNPs, including lung, heart, brain, CD4+ cells, all T cells, and bone marrow stem cells.
RSVP to save your spot for this virtual conference on COVID-19.